GlassScriptPhysician profile
Daniel Shaun Roberson
NPI 1780044610
$7,150.39
in general payments reported to CMS, 2019-2025
37 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.15 · 2022: $1,231 · 2023: $647 · 2024: $2,427 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119 · Education: $36.00 · Travel and Lodging: $9.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,683.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118.97 |
| Education | $36.00 |
| Travel and Lodging | $9.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,297.33 | 2024-2025 | Urolift, Barrigel |
| Medtronic, INC. | $995.50 | 2024-2025 | Interstim |
| Novo Nordisk INC | $675.33 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $640.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $613.55 | 2022-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $312.36 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $296.30 | 2024-2025 | Orgovyx, Gemtesa |
| Procept Biorobotics Corporation | $248.45 | 2025 | |
| Coloplast Corp | $217.08 | 2024-2025 | |
| Abbvie INC. | $176.70 | 2022-2025 | |
| Janssen Biotech, INC. | $169.52 | 2024 | Erleada, Akeega |
| Endo USA, INC. | $127.95 | 2024-2025 | Xiaflex, Aveed |
| Karl Storz Endoscopy-America | $122.36 | 2025 | |
| Urogen Pharma, INC. | $119.21 | 2025 | |
| Idorsia Pharmaceuticals US INC | $107.73 | 2023 | Quviviq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $96.99 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $89.87 | 2024-2025 | Provenge |
| Angiodynamics, INC. | $89.21 | 2025 | Nanoknife |
| Convatec INC. | $88.82 | 2024 | |
| Antares Pharma, INC. | $81.20 | 2024-2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $68.14 | 2022 | |
| Pfizer INC. | $64.76 | 2024-2025 | |
| Tempus Ai, INC | $54.77 | 2025 | Xt Cdx |
| Azurity Pharmaceuticals, INC. | $53.56 | 2025 | Azmiro |
| Abbott Laboratories | $49.01 | 2022-2023 | Freestyle Libre 2 |
| Boston Scientific Corporation | $39.30 | 2025 | Axonics, Bulkamid |
| Verity Pharmaceuticals INC. | $38.19 | 2025 | Tlando, Trelstar |
| Astellas Pharma US INC | $31.88 | 2025 | Xtandi |
| Amgen INC. | $29.67 | 2023-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $26.30 | 2025 | Keytruda Qlex, Keytruda |
| Tolmar, INC. | $25.27 | 2025 | Eligard, Jatenzo |
| Calyxo, INC. | $20.67 | 2025 | Cvac Aspiration System |
| Progenics Pharmaceuticals, INC. | $20.01 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $17.97 | 2025 | Bard Urinary Drainage Bag |
| Glaxosmithkline, LLC. | $15.99 | 2024 | Trelegy Ellipta |
| Laborie Medical Technologies Corp. | $15.11 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Heartflow, INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.